AACR 2021 | Wil FAPI PET/CT replace FDG PET/CT in the next decade?

Jeremie Calais • 22 Apr 2021

AACR 2021

Jeremie Calais, MD, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, shares his views on whether fibroblast activated protein inhibitor (FAPI) PET/CT will replace F-fluorodeoxyglucose (FDG) PET/CT imaging in the next decade, and discusses the potential role of FAPI PET/CTs in therapeutics in the future. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Jeremie Calais, MD, has received honoraria from Advanced Accelerator Applications, Blue Earth Diagnostics, Curium Pharma, GE Healthcare, IBA RadioPharma, Janssen Pharmaceuticals, POINT biopharma, Progenics/Lantheus, Radiomedix and Telix Pharmaceuticals; has participated in consultancy work with Blue Earth Diagnostics, Curium Pharma, GE Healthcare, Janssen Pharmaceuticals, POINT biopharma and Progenics/Lantheus; has participated in a speaker role for IBA RadioPharma and Telix Pharmaceuticals; has acted as a blinded independent central reader for Advanced Accelerator Applications, Progenics/Lantheus and Radiomedix, and has received research support from Progenics/Lantheus.